Timothy Ray Brown, the first person known to be cured of HIV when he had a unique type of bone marrow transplant, died in California after relapsing with cancer.

The U.S. Food and Drug Administration approved Switzerland-based pharmaceutical company Roche’s HIV-1/HIV-2 qualitative test for use on the fully automated Cobas 6800/8800 Systems.

A phase IIIb study in the United States that evaluated Dovato (dolutegravir/lamivudine) for rapid initiation of treatment after diagnosis in adults with HIV-1 found the medicine to be effective and well tolerated in the setting, indicating the feasibility of its use in Test and Treat strategies.

The U.S. Food and Drug Administration approved ViiV Healthcare’s Dovato (dolutegravir/lamivudine) as a complete regimen for the treatment of HIV-1 infection to replace the current antiretroviral regimen in adults who are virologically suppressed on a stable ARV regimen with no history of treatment failure and no known resistance to the individual components of Dovato.

Boston-based Dewpoint Therapeutics and Merck will collaborate to develop a novel mechanism for the treatment of HIV by harnessing Dewpoint’s proprietary platform for condensate-based drug discovery.

The World Health Organization is discontinuing the WHO’s trials of the malaria drug hydroxychloroquine and the combination HIV drug lopinavir/ritonavir in hospitalized patients with COVID-19 after they failed to reduce mortality.

The U.S. Food and Drug Administration approved GlaxoSmithKline Plc’s HIV drug Rukobia to treat adult patients who have run out of treatment options.

The U.S. Food and Drug Administration approved ViiV Healthcare’s Rukobia (fostemsavir) as a first-in-class treatment for HIV in adults with few treatment options available.

GlaxoSmithKline’s HIV business ViiV is within weeks of resubmitting the request for approval of the long-acting injection Cabenuva to the U.S. drug regulator.

Merck’s investigational pneumonia vaccine V114 hit the mark in two Phase III studies, including one involving adult HIV patients.